BCAB vs C · $5.9M cap vs P/E 16, rev $85.22B
Bioatla Inc (BCAB) versus Citigroup Inc. (C) — a side-by-side from cached financials, not a winner call.
Bioatla Inc (BCAB) is a biotechnology company listed on NASDAQ.
Citigroup Inc. (C) is a banks - diversified company listed on US.
Latest reported BCAB revenue for 2023-09-30 was $0. Net income was -$33.3M. BCAB currently screens at market cap $5.9M.
Latest reported C revenue for 2025-12-31 was $85.22B. Net income was $14.31B. Revenue was up 5.0% from 2024-12-31 to 2025-12-31. C currently screens at market cap $214.73B and trailing P/E 15.5.
BCAB currently screens at market cap $5.9M. C currently screens at market cap $214.73B and trailing P/E 15.5.
Not investment advice. Open the BCAB and C stock pages for the full models.
Not investment advice.